International Business Machines Corp vs Nuwellis Inc — how do they compare? International Business Machines Corp trades at $211.13 (market cap $200.20B), while Nuwellis Inc trades at $2.94 (market cap $1.09M). The key difference: International Business Machines Corp is far larger — about 183669.7× Nuwellis Inc's market cap, and International Business Machines Corp pays a 3.17% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| IBM | NUWE | |
|---|---|---|
Market Cap | $200.20B | $1.09M |
Volume | 4,481,527 | — |
Sector | Technology | Technology |
52-Week High | $329.23 | $527.46 |
52-Week Low | $211.20 | $2.80 |
Enterprise Value | $258.21B | -$722.58K |
Dividend Yield | 3.17% | — |
Signals from Pluang's Aura AI — not financial advice
IBM's stock trades at $210.5, down 1.02% over the past day, amid a bearish technical signal and recent volatility following a pre-announced Q2 2026 earnings miss. The company shows strong profitability with a net income margin of 15.61% and has beaten earnings estimates in three of the last four quarters. However, negative cash flow in 2025 and a 25% stock drop on July 14, 2026, due to lowered growth guidance have heightened investor concerns. Analyst consensus remains moderately positive with a $282.47 price target, but legal investigations into the guidance cut add uncertainty.
The outlook is cautious; solid fundamentals and a high dividend yield offer value, but execution risks and slowing revenue growth pose significant headwinds. Investment opportunity hinges on IBM's ability to stabilize performance and meet future earnings expectations, while key risks include ongoing legal scrutiny and competitive pressures in the technology sector.
NUWE trades at $3.00, up 5.26% over 24 hours, following a recent 35:1 reverse stock split effective June 26, 2026. The stock shows a bearish technical signal with all moving averages indicating sell. Fundamentally, the company reported a net loss of $17.52M in 2025, with negative profit margins, though revenue grew to $8.27M. Recent news highlights expansion in pediatric care and a $6M public offering closed in June 2026.
Outlook remains challenging due to persistent losses and high cash burn, but strategic initiatives in pediatric cardiorenal care and new patents offer growth potential. Key risks include negative ROE, reliance on financing, and competitive pressures. Analyst consensus is split evenly between Buy and Hold, reflecting cautious optimism amid financial headwinds.
Trailing returns across standard periods
Latest headlines on both assets
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →